NORRIS MEDICINES LIMITED

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Ġujarat. Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrispharma.com. Website: www.norrispharma.com

CIN No. L24230MH1990PLC058071.

PART -1 Rs. In Lakhs							
	STATEMENT OF AUDITED FINANCIAL R	ESULTS FOR	THE QUAR	TER AND YE	AR ENDED 31	.03.2015	
SI.	Particulars	d	uarter Ende	Year Ended			
No.		31.03.2015	31.12.2014	31.03.2014	31.03.2015	31.03.2014	
		Audited	Unaudited	Audited	Audited	Audited	
1	(a) Net Sales/Income from Operations	447.46	525.48	628.78	1867.79	2070.43	
	(b) Other Operating Income	0.00	0.00	0.00	12.88	11.63	
	Total Income From Operations (Net)	447.46	525.48	628.78	1880.67	2082.06	
2	Expenses				-		
	a. Cost of Materials Consumed	185.92	225.64	382.96	913.34	1213.97	
	b. Purchase of Stock in Trade	0.00	0.00	0.00	0.00	0.00	
	c. Changes in Inventories of Finished Goods,	_		_			
1	work in Progress and stock in trade	-2.69	62.97	55.91	-1.33	154.36	
	d. Employee Benfit Expenses	121.00	108.30	92.03	408.36	370.28	
	e. Depreciation and Amortisation Expense	31.01	31.54	30.79	131.23	116.72	
	f.Loss/Gain on Foreign Exchange Transactions	0.00	0.00	0.00	-0.34	0.00	
	g. Other expenditure	78.63	87.54	120.99	376.94	437.87	
	Total Expenses	413.86	515.99	682.68	1828.20	2293.20	
	Profit from operations before Other Income and Fiance Cost (1-2)	33.59	9.49	-53.90	52.47	-211.14	
	Other Income	0.06	0.16	2.10	2.03	_0.00	
	Profit before Filnance Costs (3+4)	33.65	9.65	-51.80	54.50	<u>-211.14</u>	
6	Finance Costs	13.69	14.42	10.69	53.81	44.52	
7	Profit/ Loss before Tax (5-6)	19.96	-4.77	-62.49	0.69	-255.66	
8	Tax Expense	0.00	0.00	110.37	105.04	-110.37	
9	Net profit (+)/Loss (-) for the period (7-8)	19.96	-4.77	47.88	-104.35	-145.29	
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992,58	992.58	992.58	
11	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	552.00	002.00	332.30	-463.48		
	Earnings Per Share (EPS) - Face Value of Share Rs. 10/ each (Not Annualised)	0.00	0.00	0.00	0.00	0.00	
	- Basic and diluted	0.20	-0.05	0.48	-1.04	-1.45	

NORRIS MEDICINES LIMITED

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.

Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrispharma.com. Website: www.norrispharma.com

CIN No. L24230MH1990PLC058071.

PAR	T -II						
	Select In	formation for	the Quarter	Ended 31.03	.2015		
SI. No.	Particulars	Quarter Ended 31.03.2015	Quarter Ended 31,12,2014	Quarter Ended 31.03.2014	Twelve Months ended 31.12.2015	Twelve Months ended 31.12.2014	Previous accounting year ended 31.03.2015
A 1	PARTICULARS OF SHAREHOLDING					<u></u>	
	Public Shareholding						
	-No. of shares	2450100	2450100	2450100	2450100	2450100	2450100
	-Percentage of shareholding	24.48	24.48	24.48	2 <u>4.48</u>	24.48	24.48
2	Promoters and promoter group Shareholding						
a)	Pledged/Encumbered						
	-No. of shares	Nil	Nil	Nil	Nii	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group) - Percentage of shares (as a% of the total share capital of the Company)	<u>, Nil</u>		. Nil			Nil Nil
b)	Non-encumbered						
	-No. of shares	7556900	7556900	7556900	7556900	7556900	7556900
	- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	100.00	100.00	100.00	100.00	100.00	100
	- Percentage of shares (as a% of the total share capital of the Company)	75.52	75.52	75.52	75.52	75.52	75.52

PARTICULARS	Quarter Ended 31.03.2015			
B. INVESTORS COMPLAINTS				
Pending at the beginning of the Quarter	Nil			
Received during the quarter	03			
Disposed off during the quarter	01			
Remaining unresolved at the end of the quarter	Nil			

Notes:

- 1) The above Audited Fianacial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 29.05,2015. Limited review of the above results has been carried out by the Statutory Auditors of the company.
- 2) The Company is having one segment only and therefore Segmental Reporting is not applicable.
- 3) There are no exceptional/ extraordinary items during the quarter ended 31.03.2015.
- 4) Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures

For Norris Medicines Limited

Vimal D Shah

Managing Director

Date: 29.05.2015 Place:Ankleshwar